Impact ledger
HUTCHMED (China) Limited (HCM): the developments shaping its investment case
Follow the evidence affecting HUTCHMED (China) Limited. Review the key developments below. Continue in Market Ontology to test your assumptions, examine related opportunities, and save the investment case you want to track.
Research HUTCHMED (China) Limited · $399/mo
Test assumptions, examine opportunities, and save your research.
Material developments
2026-09-24 · 6 reports
Hutchmed to Present Phase III Savolitinib NSCLC Trial Results at ESMO 2026 Congress
Channel: Direct positive clinical trial results for a key pipeline asset, increasing probability of regulatory approval and market penetration.
Bullish· 3-12m
2026-08-28 · 2 reports
China NMPA grants conditional approval for HUTCHMED's ATLED in oncology
Channel: Direct regulatory approval leading to commercial launch and revenue generation for a key product.
Bullish· 1-3m
2026-09-29 · 2 reports
AstraZeneca files US FDA NDA for savolitinib combo in MET-driven lung cancer
Channel: Regulatory progress for a co-developed drug, leading to potential milestone payments and future royalty streams from US sales.
Bullish· 3-12m
Event impact log
22 events mapped to HCM since 2026-08-28. Evidence through 2026-09-29.
| Date | Event | Channel | Direction | Horizon | Impact |
|---|---|---|---|---|---|
| 2026-09-29 | AstraZeneca files US FDA NDA for savolitinib combo in MET-driven lung cancer | Regulatory progress for a co-developed drug, leading to potential milestone payments and future royalty streams from US sales. | Bullish | 3-12m | 0.70 |
| 2026-09-29 | AstraZeneca and HUTCHMED Submit US NDA for ORPATHYS Plus TAGRISSO in Lung Cancer | Direct revenue potential from new drug combination approval, validation of pipeline asset (Orpathys). | Bullish | 3-12m | 0.70 |
| 2026-09-29 | AstraZeneca Submits US NDA for Savolitinib and Tagrisso in MET-Driven Lung Cancer | Partnered asset regulatory milestone, potential for milestone payments and future royalty revenue. | Bullish | 3-12m | 0.80 |
| 2026-09-28 | HUTCHMED Doses First Patient in Global Phase Ia Trial of HMPL-A830 | Direct progress in drug development pipeline, potential for future milestone payments and royalties, de-risking of R&D investment. | Bullish | 1-5y | 0.60 |
| 2026-09-28 | HUTCHMED and GSK Dose First Patient in Phase Ia Trial of KRAS-EGFR Conjugate HMPL-A830 | Direct R&D pipeline progress, validation of drug discovery platform, potential future milestone payments. | Bullish | 1-3m | 0.60 |
| 2026-09-28 | HUTCHMED Initiates Global Phase Ia Trial for KRAS-EGFR Conjugate | Direct R&D pipeline progress, signaling advancement of a novel oncology candidate. This is a key milestone for an early-stage asset. | Bullish | 1-3m | 0.60 |
| 2026-09-28 | HUTCHMED doses first patient in global Phase Ia trial of KRAS-EGFR conjugate | Direct progress in clinical pipeline, validating R&D investment and partnership value. | Bullish | 1-3m | 0.60 |
| 2026-09-28 | HUTCHMED doses first patient in Phase Ia trial of KRAS-EGFR conjugate HMPL-A830 | Direct progress in drug development pipeline, de-risking early-stage assets. | Bullish | 3-12m | 0.60 |
| 2026-09-28 | HUTCHMED and GSK Initiate Global Phase Ia Trial of KRAS-EGFR Conjugate HMPL-A830 | Direct pipeline progression and validation of R&D strategy. Early-stage clinical trial initiation is a positive, albeit high-risk, step. | Bullish | 1-3m | 0.60 |
| 2026-09-28 | HUTCHMED and GSK Initiate Phase Ia Trial for KRAS-EGFR Conjugate Therapy | Direct impact on pipeline value and potential future revenue streams from successful drug development. Early-stage clinical trial initiation validates R&D efforts and partnership value. | Bullish | 1-5y | 0.60 |
| 2026-09-28 | HUTCHMED Initiates Phase Ia Global Trial of First-in-Class KRAS-EGFR Conjugate | Direct R&D pipeline progression, validation of novel mechanism, potential for future milestone payments and royalties. | Bullish | 1-3m | 0.70 |
| 2026-09-24 | Hutchmed to Present Phase III Savolitinib NSCLC Trial Results at ESMO 2026 Congress | Direct positive clinical trial results for a key pipeline asset, increasing probability of regulatory approval and market penetration. | Bullish | 3-12m | 0.80 |
| 2026-09-24 | HUTCHMED and AstraZeneca Present Phase III Lung Cancer Data at ESMO | Direct positive clinical trial results for a key pipeline asset, increasing probability of regulatory approval and market penetration. | Bullish | 1-3m | 0.80 |
| 2026-09-24 | HUTCHMED and AstraZeneca present Phase III lung cancer data at ESMO 2026 | Direct positive clinical trial results for a key pipeline asset (savolitinib) in combination with a partner's drug, potentially leading to increased market share and future revenue streams. | Bullish | 1-3m | 0.85 |
| 2026-09-24 | HUTCHMED and AstraZeneca to Present Savolitinib Phase III NSCLC Data at ESMO | Direct impact from positive clinical trial data presentation, potentially leading to increased market confidence in future regulatory approvals and commercialization prospects. | Bullish | 1-3m | 0.80 |
| 2026-09-24 | HUTCHMED to Present Phase III Savolitinib Lung Cancer Data at ESMO 2026 | Direct positive clinical trial data presentation for a key pipeline asset, potentially leading to increased market interest, analyst upgrades, and future revenue prospects. | Bullish | 1-3m | 0.80 |
| 2026-08-31 | HUTCHMED and AstraZeneca Announce Positive Phase III SANOVO Trial in NSCLC | Direct positive clinical trial outcome for a key pipeline asset, leading to potential regulatory submissions and market expansion. | Bullish | 1-3m | 0.80 |
| 2026-08-31 | HUTCHMED and AstraZeneca report positive Phase III trial for Orpathys plus Tagrisso | Direct positive clinical trial outcome for a key pipeline asset, leading to potential regulatory approval and market expansion. | Bullish | 3-12m | 0.80 |
| 2026-08-31 | HUTCHMED and AstraZeneca report positive Phase III SANOVO lung cancer trial data | Direct impact from successful clinical trial results for a key pipeline asset, leading to potential regulatory approval and market expansion. | Bullish | 3-12m | 0.90 |
| 2026-08-31 | HUTCHMED and AstraZeneca Report Positive Phase III SANOVO Trial in China | Direct impact from successful clinical trial results for a key pipeline asset, increasing probability of regulatory approval and future market penetration. | Bullish | 1-3m | 0.90 |
| 2026-08-28 | China NMPA grants conditional approval for HUTCHMED's ATLED in oncology | Direct regulatory approval leading to commercial launch and revenue generation for a key product. | Bullish | 1-3m | 0.90 |
| 2026-08-28 | HUTCHMED Receives NMPA Conditional Approval for ATLED in China | Direct regulatory approval leading to market entry and revenue generation for a new drug. | Bullish | 1-3m | 0.80 |
Continue this research
Build your HUTCHMED (China) Limited investment case. Continue from the evidence above, change the assumptions the developments move, and save the work to revisit as the case develops.
This ledger is regenerated from Market Ontology's public event pipeline. View the HCM entity page →